In vitro release of arachidonic acid metabolites, glutathione peroxidase, and oxygen-free radicals from platelets of asthmatic patients with and without aspirin intolerance

Vicente Plaza, Jordi Prat, Joan Roselló, Eugeni Ballester, Isabel Ramis, Joaquim Mullol, Emilio Gelpí, Josep L L Vives-Corrons, César Picado

Abstract
Background – An abnormal platelet release of oxygen-free radicals has been described in acetylsalicylic acid (aspirin)-induced asthma, a finding which might suggest the existence of an intrinsic, specific platelet abnormality of arachidonic acid metabolism in these patients. The objective of this study was to evaluate platelet arachidonic acid metabolism in asthmatic patients with or without intolerance to aspirin.

Methods – Thirty subjects distributed into three groups were studied: group 1, 10 healthy subjects; group 2, 10 asthmatic patients with aspirin tolerance; and group 3, 10 aspirin-intolerant asthmatics. Platelets were isolated from blood, pre-incubated with H-arachidonic acid for 30 minutes and then incubated for 10 minutes with platelet activating factor (PAF) and aspirin. Cyclo-oxygenase (thromboxane, PGE, PGI, and HHT) and lipoxygenase (12-HETE) arachidonic acid metabolites were measured by high pressure liquid chromatography. Release of oxygen free radicals after incubation with PAF and aspirin was measured by chemiluminescence. Platelet levels of glutathione peroxidase (GSH-Px) were also measured using spectrophotometry.

Results – Platelets from aspirin-intolerant asthmatic patients produced higher quantities of arachidonic acid metabolites than the control group at baseline conditions. This increase was significant only for lipoxygenase products. No differences were found amongst the three groups in the response of arachidonic acid metabolism to PAF and aspirin. Incubation with aspirin but not with PAF caused an increase in oxygen-free radical production in aspirin-intolerant patients whereas in aspirin-tolerant patients PAF, rather than aspirin, was the more potent stimulus for oxygen-free radical production. No differences in GSH-Px levels were found amongst the three groups.

Conclusions – These results suggest that the platelet lipoxygenase pathway is activated in aspirin-intolerant patients and that the production of oxygen-free radicals may differentiate aspirin-tolerant from aspirin-intolerant asthmatic subjects. Our study, however, does not support the hypothesis that an increase in lipoxygenase products might be responsible for oxygen-free radical production. Moreover, a lowered platelet GSH-Px activity does not seem to be involved in this phenomenon.

Keywords: bronchial asthma, aspirin-sensitive asthma, oxygen-free radicals, arachidonic acid metabolites, glutathione peroxidase.

In some asthmatic patients acetylsalicylic acid (aspirin) and other non steroidal anti-inflammatory drugs (NSAIDs) precipitate asthma attacks. Although during the last two decades numerous studies have been carried out to investigate this phenomenon, the mechanism(s) responsible remains unknown. Szczeklik et al showed that all drugs that share the common property of inhibiting the cyclooxygenase pathway can provoke asthma attacks. This finding has suggested that, in aspirin-induced asthma, blockade of the cyclooxygenase enzyme might divert arachidonic acid metabolism from the cyclooxygenase pathway, leading to both an excessive production of bronchoconstrictor leukotrienes as well as a lack of bronchodilator PGE,.

It has also been proposed that aspirin intolerance is the consequence of viral infection, but this hypothesis has yet to be substantiated by any experimental evidence. A recent study has shown a significant rise in urinary LTE levels after aspirin ingestion in aspirin-sensitive patients. Picado et al have also reported that intranasal challenge with lysine-aspirin is associated with an increased concentration of peptide leukotrienes in nasal lavage in aspirin-sensitive subjects. The demonstration of increased leukotriene release in aspirin-induced asthma suggests that peptide...
leukotrienes have a role in the pathogenesis of aspirin sensitivity. The cellular source for the augmented leukotriene production is still unknown.

Although the role of platelets in aspirin-induced asthma is a matter of debate, some recent findings suggest that these cells might be involved in this peculiar clinical syndrome. Ameisen et al. have described an abnormal platelet release of oxygen-free radicals from aspirin-sensitive asthmatics exposed to aspirin in vitro—finding that might suggest the existence of an intrinsic, specific platelet abnormality of arachidonic acid metabolism in these patients. Recent studies have also shown lowered glutathione peroxidase (GSH-Px) activity in platelets of aspirin-sensitive asthmatics and, since GSH-Px plays an important part in the protection against oxidative damage, it has been suggested that aspirin-related asthma attacks are due in part to a deficit in this scavenger. On the other hand, although no consistent abnormality in arachidonic acid metabolism has ever been shown in aspirin-sensitive patients, it seems reasonable to suspect that the abnormal response of a patient’s platelets to NSAIDs is due to a change in the balance of arachidonic acid metabolism. If this hypothesis was true we might expect a different pattern of release of arachidonic acid metabolites from the platelets of aspirin-sensitive patients compared with both aspirin-insensitive asthmatics and healthy subjects.

Because release of oxygen-free radicals can occur after activation of both the cyclo and lipooxygenase pathways, we reasoned that aspirin must increase the production of oxygen-free radicals in aspirin-intolerant asthmatic subjects by increasing the activity of either one or both pathways. In order to assess this potential aspirin action we compared the effects of aspirin with platelet activating factor (PAF), a well known potent platelet activator.

It is interesting to note that the three postulated intrinsic platelet abnormalities (excessive production of oxygen-free radicals, lowered GSH-Px activity, and an increased production of lipooxygenase metabolites) have never been evaluated in a study designed to assess their interrelation in the pathogenesis of aspirin-induced idiosyncratic reactions. The aim of this study was to evaluate these abnormalities and their possible relationship in the origin of aspirin-induced asthma.

**Mean (SD) characteristics of subjects**

<table>
<thead>
<tr>
<th></th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Age (years)</td>
<td>39-4 (7)</td>
<td>38-6 (16)</td>
<td>40-2 (12)</td>
</tr>
<tr>
<td>% Male/female</td>
<td>45/55</td>
<td>45/55</td>
<td>45/55</td>
</tr>
<tr>
<td>Smoker or ex-smoker</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Rhinitis (%)</td>
<td>13</td>
<td>90</td>
<td>100</td>
</tr>
<tr>
<td>Years of rhinitis</td>
<td>13 (13)</td>
<td>18 (16)</td>
<td>18-2 (16)</td>
</tr>
<tr>
<td>Nasal polyps (%)</td>
<td>10</td>
<td>73*</td>
<td></td>
</tr>
<tr>
<td>Years of asthma</td>
<td>11-1 (5-4)</td>
<td>11-2 (10-1)</td>
<td></td>
</tr>
<tr>
<td>Inhaled steroid treatment (%)</td>
<td>36</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>FEV₁ (%predicted)</td>
<td>77 (35)</td>
<td>83 (13)</td>
<td></td>
</tr>
<tr>
<td>Frick test (+) (%)</td>
<td>70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eosinophils in blood</td>
<td>228 (201)</td>
<td>363 (355)</td>
<td></td>
</tr>
<tr>
<td>Score severity of the disease</td>
<td>3-4 (1-9)</td>
<td>4-4 (2-1)</td>
<td></td>
</tr>
</tbody>
</table>

Severity of the disease was assessed taking into account clinical symptoms (score 1–3), degree of bronchial obstruction (1–4) and the amount of treatment needed to control symptoms (1–3). 

*p<0.005 (2* test).

**Methods**

**SUBJECTS**

Ten health subjects (group 1), 10 aspirin-tolerant asthmatic patients (group 2), and 10 aspirin-intolerant asthmatic patients (group 3) were included in the study. Characteristics of the three groups are depicted in the table. Asthma was diagnosed when there was a history of shortness of breath, wheezing, and evidence of reversible airways obstruction. Diagnosis of aspirin intolerance was made on the basis of a clear history of two or more acute asthmatic attacks precipitated by aspirin or other NSAIDs. Aspirin intolerance was confirmed by nasal challenge with aspirin according to a previously described method. Only patients with a predominant asthmatic response were included (none had isolated urticarial/anaesthesia reactions without asthmatic exacerbation). Aspirin-tolerant asthmatics denied any aspirin-induced reaction. The healthy volunteers were recruited for the study from the staff of our institution. The criteria for inclusion were current good health and absence of any treatment at the time of recruitment. All subjects gave informed and signed consent to participate in the study, which was approved by the ethical committee of our institution.

The three groups were similar in age and sex distribution. As expected, the proportion of aspirin-intolerant patients suffering from nasal polyps was higher than in the aspirin-tolerant group. Severity of disease was assessed according to a score taking into account clinical symptoms (score 1–3), severity of bronchial obstruction measured by forced spirometry (score 1–4), and the amount of treatment needed to control symptoms (score 1–3). There were no differences between tolerant and intolerant patients with respect to either clinical score or bronchial obstruction. A higher proportion of aspirin-intolerant patients received treatment with inhaled steroids, but the difference was not significant. None of them, however, were on oral steroid treatment.

**PLATELET ISOLATION**

Between 08.30 and 09.30 hours a 30 ml specimen of blood was drawn from the antecubital vein of each of the 30 subjects. Platelet-rich plasma was obtained by a method previously described by Levine and Fedorko and modified by Rao et al. Briefly, whole blood was centrifuged at 225 g for 15 minutes at 37°C. In order to discard abnormal platelets and previous ingestion of any antiaggregant substance, aggregation studies were performed by adding arachidonic acid to 450 μl platelet-rich plasma according to Born's method (Aggregometer PA-3210 Hitachi). Platelets from the platelet-rich plasma were washed twice with equal volumes of citrate-citric acid-dextrose (93 mmol/l sodium citrate, 70 mmol/l citric acid, and 140 mmol/l dextrose), pH 6.5, containing 5 mmol/l adenosine and 3 mmol/l theophylline and centrifuged at 750 g for 15 minutes at 37°C. The final pellet was resuspended in Hank's balanced salt solution to a final platelet count of 300 × 10⁶ platelets/ml.
INCUBATION OF WASHED HUMAN PLATELETS WITH ARACHIDONIC ACID

To determine arachidonic acid metabolites 4 ml of the final platelet-rich plasma suspension was distributed into three plastic tubes (1 ml in each). Platelets were preincubated with [3H]-arachidonic acid (2 μCi/tube). Thromboxane B2, E2, and metabolite X were then added to the three tubes. One tube was used as a control. Ca2+ and Mg2+ salts were added to each tube and incubation was carried out for 10 minutes before stopping the reaction by adding 2 ml Hank’s solution at 37°C. An incubation time of 10 minutes was used because the maximum production of both cyclooxygenase and lipoygenase products after PAF stimulation occurred at this time in a preliminary study in three subjects. After centrifugation at 1000 g for 15 minutes at 4°C supernatants were stored at -70°C until assay. The effects of PAF and aspirin on arachidonic acid metabolite synthesis were expressed as increments with respect to the values obtained from the control tube.

EXTRACTION AND PURIFICATION

Eicosanoid extraction was carried out according to methods previously described.21 Briefly, supernatants of platelet incubations were acidified to pH 4 with 1N HCl and processed through C18 reversed phase cartridges (Baker, Phillipsburg, New Jersey, USA) which had been pretreated with both 10 ml methanol and 10 ml water (pH 4). After sample addition, cartridges were washed with 10 ml water and eicosanoids were eluted with 5 ml methanol and evaporated under helium stream. Dried residues were stored at -70°C until HPLC assay.

HIGH PRESSURE LIQUID CHROMATOGRAPHY (HPLC) ANALYSIS

HPLC separation of [3H]-labelled metabolites was performed using two Spectroflow 400 pumps (Applied Biosystems, Ramsey, New Jersey, USA) and products were monitored with a radioactivity detector (Ramona, Raytest, Straubenhardt, Germany). The metabolites were measured using a radiochromatographic system from Nuclear Interface (Münster, Germany). Formic acid 40 mM titrated to pH 3.15 with triethylamine/acetonitrile was employed as a mobile phase. The elution conditions involved an initial isocratic elution for 14 minutes (33% acetonitrile), a linearly increasing acetonitrile gradient (33–60%) for eight minutes, an isocratic elution for nine minutes (60% acetonitrile), a linearly increasing acetonitrile gradient (60–100%), and an isocratic elution for five minutes (100% acetonitrile). The flow rate was 1.5 ml/min. Reversed phase chromatography was performed on a Spherisorb ODS-2 (250 4.6 mm, 10 μm) column (Phase Separations Ltd, Deeside, UK). These conditions allowed a total separation of prostanoids, HHT, 12-HETE, and arachidonic acid.

CHEMILUMINESCENCE ASSAY

Platelet chemiluminescence was measured according to the method of Ameisen et al22 with a few modifications. Light emission was measured in a Monolight 2001 Lumac (Sonoco Ltd, Batley, UK) which converted light emission into millivolt readings. Platelets (75 x 10^9) in 500 μl Hank’s solution were tested in the presence of luminol 418 μM and horseradish peroxidase (720 μM). Results were expressed in terms of the change in the light emission by dividing the maximum value of light emission obtained immediately after the addition of aspirin to the platelets by the light emission obtained with platelets in the presence of luminol and horseradish peroxidase (basal value). To investigate the effects of aspirin and PAF on chemiluminescence in more detail, different doses of aspirin (20 μM, 40 μM, 60 μM, 80 μM and 100 μM) and PAF (25 μM, 50 μM, 100 μM and 150 μM) were used.

GLUTATHIONE PEROXIDASE (GSH-Px) ASSAY

GSH-Px activity was determined according to a method previously described.21 Washed platelets were resuspended in PO4 buffer, pH 7.4, containing 2 x 10^–4 M NADPH, 10^-3 M aminocaproic acid, 10^-2 M ethylene diamine tetraacetic acid disodium salt, and 10^-3 M 2-mercaptoethanol. The suspension was frozen in liquid nitrogen and the supernatant was obtained by centrifugation (30,000 g for 10 minutes). Five ml of the platelet lysate were taken and redissolved in 100 μl Tris-HCl 1 M at pH 8, 20 μl glutathione (GSH) 0-1 M, 100 μl GSH-R (glutathione reductase) 10 U/ml,
In vitro release of arachidonic metabolites

Figure 2  Arachidonic acid metabolite basal values: □ = cyclo-oxidase products (TXB₂, PGF₂α, PGE₂, and HHT) and ▪ = lipoxygenase products (12-HETE and metabolite X). Aspirin-intolerant patients had a higher metabolic activity than the other two groups, although the difference was only statistically significant for lipoxygenase products (*p<0.005). CPS = counts per second.  

100 μL NADPH 2 μM, and 665 μL H₂O. The mixture was incubated at 37°C for 10 minutes. The reaction was initiated by adding 10 μL t-butyl-hydroperoxide 7 μM (1/1000). Conversion of NADPH to NADP was made by measuring the change of absorbance at 340 nm using a spectrophotometer (Kontron, Uvikon 860). The non-enzymatic oxidation of NADPH was determined using an identical assay system without the addition of the platelet lysate (control tube). The increment of absorbance in the control tube was subtracted from that obtained with the platelet lysate to determine the true GSH-Px activity. Values obtained were expressed as mU per 10⁶ platelets.

DATA ANALYSIS

Analysis of variance and Kruskal-Wallis tests were used to evaluate differences among the three groups. The Mann-Whitney test was used to assess differences between the two groups and the χ² test and Pearson’s correlation were also used when appropriate. Significance level in all tests was p<0.05.

Results

ARACHIDONIC ACID METABOLITES

Basal values

Platelets from aspirin-intolerant patients showed a significant basal activity and produced more cyclo-oxidase and lipoxygenase products than platelets from both aspirin-tolerant patients and healthy subjects. No differences were observed between aspirin-tolerant patients and healthy subjects. In order to analyse the two pathways of platelet arachidonic acid metabolism, cyclo-oxidase and lipoxygenase products (TXB₂, PGF₂α, PGE₂, and HHT) were grouped and compared with lipoxygenase metabolites (12-HETE and metabolite X). Aspirin-intolerant asthmatics showed more cyclo-oxidase and lipoxygenase products than the other groups (fig 2). Although the two metabolic pathways were more active in aspirin-intolerant patients, only the increase in lipoxygenase products reached statistical significance between the aspirin-intolerant and the control group (p = 0.005).

Response to PAF

The response of cyclo-oxidase and lipoxygenase metabolites to PAF is shown in fig 3. 12-HETE was the metabolite that increased most in the three groups. No significant changes were detected for PGE₂ and PGF₂α. PAF caused a significant increase in TXB₂ and HHT release only in aspirin-intolerant patients. It stimulated the lipoxygenase pathway more (12-HETE increased 255% for the three groups

Figure 3  Platelet arachidonic acid metabolite response to platelet activating factor (PAF). 12-HETE was the metabolite that increased most in the three groups. No significant changes were detected for PGE₂ and PGF₂α. PAF caused a significant increase in TXB₂ and HHT release only in aspirin-intolerant patients (*p<0.05). CPS = counts per second.
Figure 4 Platelet arachidonic acid metabolite response to aspirin. No differences in the production of either cyclo-
oxidase or lipoxygenase metabolites were detected among the three groups after incubation with aspirin. CPS = counts per second.

- Controls
- Aspirin tolerant
- Aspirin intolerant

Figure 5 Production of oxygen-free radicals measured by chemiluminescence (CL) with different doses of (A) aspirin and (B) platelet activating factor (PAF). Results are expressed in terms of change (%CL) in light emission by dividing the maximum value of CL obtained immediately after the addition of aspirin to platelets, by the CL obtained with platelets in the presence of both luminol and horseradish peroxidase (basal value).

(A) The maximal burst of CL was obtained with 40 μl aspirin. Changes were statistically significant only for asthmatics (Friedman two way ANOVA and Wilcoxon’s tests: *p<0.01, **p<0.001). Although a greater response was observed in aspirin-intolerant patients than in both aspirin-tolerant and healthy subjects, differences did not reach significance. (B) The maximal burst of CL was obtained with 50 μl PAF in aspirin-tolerant patients. In platelets from aspirin-intolerant patients no increase in light emission could be detected. Changes were significant for aspirin-tolerant patients and healthy subjects (Friedman two way ANOVA and Wilcoxon’s tests, *p<0.01, **p<0.001).

Response to aspirin
Aspirin caused the least quantitative changes and none of these changes reached statistical significance (fig 4). No differences in the production of lipoxygenase metabolites were detected among the three groups after incubation with aspirin.

Platelet Chemiluminescence
For technical reasons only nine patients from each group were studied. PAF and aspirin-induced platelet chemiluminescence at different doses is presented in fig 5. Platelets from aspirin-sensitive patients showed the maximal burst of chemiluminescence after being incubated with 40 μl aspirin. The addition of different doses of aspirin to platelets from healthy and aspirin-tolerant asthmatic subjects produced a mild and non-significant increase in light emission whereas in aspirin-intolerant asthmatics a moderate and significant response in light emission was detected with 40 μl aspirin. Although aspirin-intolerant patients showed higher chemiluminescence values than the other two groups, the difference was not significant. Only three of the nine aspirin-intolerant patients, however, showed a marked increase in chemiluminescence.

PAF produced a considerable increase in light emission in aspirin-tolerant patients and healthy subjects. However, in contrast to aspirin, PAF had no effect in aspirin-intolerant patients. In aspirin-tolerant patients 25 μl and 50 μl PAF significantly increased chemi-
In vitro release of arachidonic metabolites

luminescence (p<0.005). The light emission response was also statistically significant with 50 μl PAF in healthy subjects (p<0.005). In aspirin-intolerant patients the increase in light emission after incubation with 40 μl aspirin was significantly higher than after incubation with PAF (50 μl) (p<0.05).

GSH-Px activity
For technical reasons only eight subjects from each group were studied. The mean (SD) results of the GSH-Px assay were 369.6 (82) mU × 10⁹/platelet in controls (group 1); 340.6 (64) mU × 10⁹/platelet in aspirin-tolerant asthmatics (group 2); and 330.8 (58) mU × 10⁹/platelet in aspirin intolerant asthmatics (group 3) (fig 6). No significant differences in GSH-Px determinations were found either between healthy and asthmatic subjects, or between both groups of patients.

Discussion
There were three major findings in this study. Firstly, platelet arachidonic acid metabolism was more active in aspirin-intolerant patients than in both aspirin-tolerant and healthy subjects. Secondly, no differences in the response of arachidonic acid metabolism to either aspirin or PAF were found among the three groups and, finally, incubation with aspirin but not with PAF caused an increase in light emission in aspirin-intolerant patients whereas in aspirin-tolerant patients PAF rather than aspirin was the more potent stimulus for oxygen-free radical production.

The overproduction of arachidonic acid metabolites detected in our study could result from an actual increase in the release of these products, but may also be the consequence of differences in the kinetics of the release of these metabolites between aspirin-intolerant patients and aspirin-tolerant and healthy subjects. The method used in this study (single time point) does not allow this question to be answered. Only a kinetic analysis with different substrate concentrations would allow us to elucidate the cause of the overactivity of the arachidonic acid pathway in aspirin-intolerant patients.

The mechanism responsible for the different response in light emission between aspirin-intolerant and aspirin-tolerant patients to aspirin and PAF is also unclear, but our findings suggest the presence of two binding sites for PAF - a phenomenon recently described in eosinophils.22,23 In these cells occupation of the high affinity PAF receptor correlates with prostanoid release whereas occupancy of the low PAF receptor is associated solely with the generation of ORL. In our study we did not detect differences in prostanoid release after PAF stimulation among the three groups; the same stimuli, however, increased the production of oxygen-free radicals in aspirin-tolerant patients and healthy subjects but not in aspirin-intolerant asthmatic patients. This phenomenon suggests the possible existence in platelets, as in eosinophils, of two PAF receptors and that in aspirin-intolerant asthmatic subjects the low affinity PAF receptor is down-regulated for unknown reasons. Our results reinforce previous findings which suggest that the production of oxygen-free radicals may differentiate aspirin-tolerant from aspirin-intolerant asthmatics. Although Ameisen et al have suggested that the increased oxygen-free radical production by aspirin in aspirin-intolerant patients is caused by the generation of lipoxigenase metabolites, our results do not support this hypothesis. Similarly, Nizankowska et al could not detect differences in the production of 12-HETE between healthy subjects and NSAID-intolerant patients after aspirin provocation.

The second hypothesis suggests that the supposed specific abnormality of arachidonic acid metabolism is localised in the cyclo-oxygenase pathway. Exogenous arachidonic acid is rapidly transformed by platelets into the prostaglandin endoperoxide PGH₂. This metabolic step is catalysed by cyclo-oxygenase. PGH₂ is a very short lived compound which is rapidly transformed into PGH₃ via a hydroperoxidase.25 Ameisen et al have shown, in a series of experiments, that alterations in the synthesis of PGH₂ endoperoxides may be responsible for the generation of oxygen-free radicals by the platelets of patients with NSAID intolerance. These authors have demonstrated that two different antagonists of the platelet PGH₂ receptor (trimetoquinol and PTOH) may precipitate aspirin-like reactions in platelets from aspirin-intolerant asthmatics, and that this reaction may be prevented by the addition of non-metabolisable analogues of the unstable PGH₂. These results suggest that aspirin-induced asthma might not be merely the consequence of a cyclo-oxygenase blockade, as previously proposed, and that an ongoing synthesis of PGH₃ and the interaction of PGH₃ with its platelet receptor, might play a part in aspirin-induced asthma.10

We only detected an increased production of oxygen-free radicals in 33% of our aspirin-intolerant patients, a figure which contrasts with the study of Ameisen et al who found a 100% positive aspirin-specific increase in the generation of oxygen-free radicals after stimulation of platelets from aspirin-sensitive patients. Other authors, however, have also failed to demonstrate this universal response of aspirin-sensitive patients.12,13,20,27
with our results, Pearson and Suarez-Mendez reported that only 32% of their aspirin-sensitive asthmatics released oxygen-free radicals in the presence of aspirin. Other authors, however, could not detect an abnormal aspirin-induced platelet release of oxygen metabolites either by chemiluminescence or other methods. Differences in the methodology and in the patients studied might account for these discrepancies.

In keeping with Stone et al we were unable to detect differences in platelet GSH-Px activity between asthmatic and healthy subjects. These findings contrast with those of Hasselmark et al who found significantly lower GSH-Px activity in patients with intrinsic asthma than in a control group. Pearson and Suarez-Mendez also found that the mean platelet GSH-Px activity was significantly lower in subjects with aspirin-induced asthma than in a healthy control group. Nevertheless, this difference could not be detected between aspirin-tolerant asthmatics and the control group. Clinical differences may account for the discrepancy in these results.

A more active disease is probably associated with an increased production of reactive oxygen radicals which may inactivate the GSH-Px. This hypothesis is supported by the observation of Bibi et al who demonstrated a close correlation between asthma severity and erythrocyte GSH-Px activity. They found that GSH-Px levels were significantly lower during exacerbation of asthma than during stable clinical conditions. Similarly, Pearson and Suarez-Mendez also observed that platelet GSH-Px activity was lower in patients with symptoms of severe asthma than in those with mild disease. We think that the platelet GSH-Px activity of our patients and healthy subjects did not differ because only mild asthmatics were included in the study. Moreover, asthmatics studied by Malmgren et al were not receiving any kind of treatment, while our patients and those in the study by Stone et al were treated with inhaled steroids (some of the latter were also receiving oral steroids). The possible effects of these treatments on platelet levels of GSH-Px cannot be overlooked.

In summary, our study shows a different in vitro response to aspirin and PAF of platelets from aspirin-tolerant and aspirin-intolerant asthmatic subjects. These results support previous findings suggesting that the production of oxygen-free radicals by platelets may differentially inactivate aspirin from aspirin-intolerant patients. Although the mechanisms involved in this response are unclear, our study does not support the presumed increase in lipoxygenase metabolites by inhibition of the cyclooxygenase pathway as the cause of oxygen-free radical production. Reduced platelet GSH-Px activity does not seem to be responsible for the pathogenesis of this intriguing phenomenon.

Supported by grants from Comisión Asesora Interministerial Ciencia y Tecnología (CAICYT) (PB 86/0594) and Fondo Investigaciones Sanitarias (FIS) (89/0396).